|
1
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the world health organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Polyatskin IL, Artemyeva AS and Krivolapov
YA: Revised WHO classification of tumors of hematopoietic and
lymphoid tissues, 2017 (4th edition): Lymphoid tumors. Arkh Patol.
81:59–65. 2019.(In Russian). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Swerdlow SH, Campo E and Harris NH: WHO
classification of tumors of hematopoietic and lymphoid tissues. Int
Agency Res Cancer. 68–71. 2008.
|
|
4
|
Lin P and Medeiros LJ: Lymphoplasmacytic
lymphoma/waldenstrom macroglobulinemia: An evolving concept. Adv
Anat Pathol. 12:246–255. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baehring JM, Hochberg EP, Raje N,
Ulrickson M and Hochberg FH: Neurological manifestations of
waldenstrom macroglobulinemia. Nat Clin Pract Neurol. 4:547–556.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yun S, Johnson AC, Okolo ON, Arnold SJ,
McBride A, Zhang L, Baz RC and Anwer F: Waldenström
macroglobulinemia: Review of pathogenesis and management. Clin
Lymphoma Myeloma Leuk. 17:252–262. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niu T: The interpretation of version
1.2018 of the NCCN guidelines for waldenstr(o)m's
macroglobulinemia/lymphoplasmacytic lymphoma. West China Med J.
33:393–397. 2018.(In Chinese).
|
|
8
|
Hematology Oncology Committee of China
Anti-Cancer Association, . Leukemia & Lymphoma Group Society of
Hematology at Chinese Medical Association; Union for China Lymphoma
Investigators: The consensus of the diagnosis and treatment of
lymphoplasmacytic lymphoma/Walderström macroglobulinemia in China
(2016 version). Zhonghua Xue Ye Xue Za Zhi. 37:729–734. 2016.(In
Chinese),. PubMed/NCBI
|
|
9
|
He J, Hu LW and Gu XK: Lymphoplasmacytic
lymphoma with the coexistence of monoclonal IgM-kappa and
IgG-kappa: A case report and literature review. J Clin Hematol.
32:219–221. 2019.(In Chinese).
|
|
10
|
Zhang M, Hong F and Fu X: Three cases of
lymphoplasmacytic lymphoma were reported and reviewed in the
literature. Chinese Tumor Clin. 37:1190–1191. 2010.
|
|
11
|
Ngo VN, Young RM, Schmitz R, Jhavar S,
Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al:
Oncogenically active MYD88 mutations in human lymphoma. Nature.
470:115–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hunter ZR, Xu L, Yang G, Tsakmaklis N, Vos
JM, Liu X, Chen J, Manning RJ, Chen JG, Brodsky P, et al:
Transcriptome sequencing reveals a profile that corresponds to
genomic variants in waldenström macroglobulinemia. Blood.
128:827–838. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shin SY, Lee ST, Kim HY, Park CH, Kim HJ,
Kim JW, Kim SJ, Kim WS and Kim SH: Detection of MYD88 L256P in
patients with lymphoplasmacytic lymphoma/waldedstrom
macorglobulinemia and other B-cell non-hodgkin lyphomas. Blood Res.
51:181–186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kristinsson SY and Landgren O: What causes
Waldenström's macroglobulinemia: Genetic or immune-related factors,
or a combination? Clin Lymphoma Myeloma Leuk. 11:85–87. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao Y, Hunter ZR, Liu X, Xu L, Yang G,
Chen J, Patterson CJ, Tsakmaklis N, Kanan S, Rodig S, et al: The
WHIM-like CXCR4 (S338X) somatic mutation activates AKT and ERK, and
promotes resistance to Ibrutinib and other agents used in the
treatment of Waldenström macroglobulinemia. Leukemia. 29:169–176.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ngo HT, Leleu X, Lee J, Jia X, Melhem M,
Runnels J, Moreau AS, Burwick N, Azab AK, Roccaro A, et al:
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenström
macroglobulinemia. Blood. 112:150–158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Varettoni M, Zibellini S, Defrancesco I,
Ferretti VV, Rizzo E, Malcovati L, Gallì A, Porta MGD, Boveri E,
Arcaini L, et al: Pattern of somatic mutations in patients with
Waldenström macroglobulinemia or IgM monoclonal gammopathy of
undetermined significance. Haematologica. 102:2077–2085. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Konoplev S, Medeiros LJ, Bueso-Ramos CE,
Jorgensen JL and Lin P: Immunophenotypic profile of
lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin
Pathol. 124:414–420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ghobrial IM, Fonseca R, Greipp PR, Blood
E, Rue M, Vesole DH and Gertz MA; Eastern Cooperative Oncology
Group, : Initial immunoglobulin M ‘flare’ after rituximab therapy
in patients diagnosed with Waldenström macroglobulinemia: An
eastern cooperative oncology group study. Cancer. 101:2593–2598.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Simon L, Fitsiori A, Lemal R, Dupuis J,
Carpentier B, Boudin L, Corby A, Aurran-Schleinitz T, Gastaud L,
Talbot A, et al: Bing-Neel syndrome, a rare complication of
Waldenström macroglobulinemia: Analysis of 44 cases and review of
the literature. A study on behalf of the French Innovative Leukemia
Organization (FILO). Haematologica. 100:1587–1594. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ghobrial IM, Hong F, Padmanabhan S, Badros
A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, et
al: Phase II trial of weekly bortezomib in combination with
rituximab in relapsed or relapsed and refractory Waldenström
macroglobulinemia. J Clin Oncol. 28:1422–1428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haider S, Latif T, Hochhausler A, Lucas F
and Abdel Karim N: Waldenstrom's macroglobulinemia and peripheral
neuropathy, organomegaly, endocrinopathy, monoclonal gammopathy,
and skin changes with a bleeding diathesis and rash. Case Rep Oncol
Med. 2013:8908642013.PubMed/NCBI
|
|
23
|
Brown R and Ginsberg L: POEMS syndrome:
Clinical update. J Neurol. 266:268–277. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Souchet L, Levy V, Ouzegdouh M, Tamburini
J, Delmer A, Dupuis J, Le Gouill S, Pégourié-Bandelier B,
Tournilhac O, Boubaya M, et al: Efficacy and long-term toxicity of
the rituximab-fludarabine-cyclophosphamide combination therapy in
Waldenstrom's macroglobulinemia. Am J Hematol. 91:782–786. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feugier P, Van Hoof A, Sebban C,
Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E,
Tilly H, Morschhauser F, et al: Long-term results of the R-CHOP
study in the treatment of elderly patients with diffuse large
B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de
l'Adulte. J Clin Oncol. 23:4117–4126. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Coiffier B, Thieblemont C, Van Den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: A study by the Groupe
d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Foà R, Del Giudice I, Cuneo A, Del Poeta
G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM,
Cortelezzi A, et al: Chlorambucil plus rituximab with or without
maintenance rituximab as first-line treatment for elderly chronic
lymphocytic leukemia patients. Am J Hematol. 89:480–486. 2014.
View Article : Google Scholar : PubMed/NCBI
|
